Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
U.S. FDA IND acceptance and IRB approval in place for investigator-sponsored trial, expected to be initiated in the second quarter of 2021 U.S. FDA IND acceptance and IRB approval in place for investi
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q4 2020 Results - Earnings Call Transcript
11:48pm, Monday, 01'st Mar 2021
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q4 2020 Results - Earnings Call Transcript
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue Estimates
06:57pm, Monday, 01'st Mar 2021
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stoc
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
04:01pm, Monday, 01'st Mar 2021
XEN1101 Phase 2b “X-TOLE” Clinical Trial in Adult Focal Epilepsy on Track for Topline Data in Third Quarter of 2021
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results
08:45am, Tuesday, 23'rd Feb 2021
Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference Xenon to Participate in Fireside Discussion at SVB Leerink 10th Annual Global Healthcare Conference
Pre-Clinical Data Support the Potential Benefit of XEN1101 to Treat Depression and Anhedonia
Early, Promising Data from Physician-Led Phase 2 Open Label Clinical Trial Support XEN007 as a Potential Treatment of Childhood Absence Epilepsy (CAE) Early, Promising Data from Physician-Led Phase 2
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
09:00am, Friday, 13'th Nov 2020
BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chie
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call Transcript
03:01am, Sunday, 08'th Nov 2020
Xenon Pharmaceuticals Inc. (XENE) CEO Simon Pimstone on Q3 2020 Results - Earnings Call Transcript
Xenon Pharmaceuticals: Updates To Thesis, Low Valuation With Multiple Catalysts In 2021
03:38pm, Wednesday, 04'th Nov 2020
Shares have risen by 15% since my March recommendation, but EV of around $180 million appears cheap contrasted to multiple opportunities in epilepsy that they are pursuing. I provide a recap of our bu
BURNABY, British Columbia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its third quarter
